MSCT finds role in bone marrow lesion diagnosis
Whole-body, low-dose CT studies of bone marrow lesions performed on 16-slice scanners are more sensitive, faster, and cheaper than conventional CT or MR imaging, according to researchers at the University of Munich's Institute of Clinical Radiology.
Whole-body, low-dose CT studies of bone marrow lesions performed on 16-slice scanners are more sensitive, faster, and cheaper than conventional CT or MR imaging, according to researchers at the University of Munich's Institute of Clinical Radiology.
Dr. Sonja Buhmann and colleagues evaluated 40 patients with proven multiple myeloma, who were divided in two groups of 20 each. Both groups underwent whole-body scanning, the first group with effective doses of 100 mAs and the other at 50 mAs.
The researchers detected all the osteolytic lesions in both groups and are now moving toward a standard 50-mAs dose protocol, Buhmann reported in a scientific session at the RSNA meeting.
Imaging protocols included 16-row scanning with 3-mm axial and sagittal slice reconstruction and 1.5 collimation at 120 kVp. At a mean radiation dose of 10 mSv and 5 mSv, respectively, each group had similarly acceptable image quality scores.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
